

## Literaturliste

### **Epitheliale Vorläuferläsionen – Differentialdiagnostik, Entartungspotential und Therapie**

*Priv.-Doz. Dr. Dr. Matthias Kreppel, Dr. Tim Backhaus, Dennis-Akuamo-Boateng, Priv.-Doz. Dr. Dr. Martin Scheer, Priv.-Doz. Dr. Hans-Joachim Nickenig, Univ. Prof. Dr. Dr. Joachim E. Zöller, Priv.-Doz. Dr. Dr. Daniel Rothamel*

Oralchirurgie Journal 3/14

1. Driemel O, Hertel K, Reichert TE, Kosmehl H. Aktuelle Klassifikation der Präkursorläsionen des oralen Plattenepithelkarzinoms - Prinzipien der WHO-Klassifikation 2005. *Mund Kiefer GesichtsChir* 2006;10:89-93.
2. Amagasa T, Yamashiro M, Uzawa N. Oral premalignant lesions: from a clinical perspective. *Int J Clin Oncol* 2011;16:5-14.
3. Neville BW, Day TA. Oral cancer and precancerous lesions. *CA: a cancer journal for clinicians* 2002;52:195-215.
4. Scully C, Bagan J, Hopper C, Epstein J. Oral cancer: Current and future diagnostic techniques. *American journal of dentistry* 2008;21:199-209.
5. Kreppel M, Rothamel D, Zöller J, Scheer M. Diagnostik und Therapie des oralen Plattenepithelkarzinoms. *Oralchirurgie Journal* 2012:6-15.
6. Napier SS, Speight PM. Natural history of potentially malignant oral lesions and conditions: an overview of the literature. *J Oral Pathol Med* 2008;37:1-10.
7. van der Waal I. Potentially malignant disorders of the oral and oropharyngeal mucosa; terminology, classification and present concepts of management. *Oral oncology* 2009;45:317-23.
8. Reichart PA. Oral mucosal lesions in a representative cross-sectional study of aging Germans. *Community Dent Oral Epidemiol* 2000;28:398.
9. Gupta PC, Mehta FS, Daftary DK, et al. Incidence rates of oral cancer and natural history of oral precancerous lesions in a 10-year follow-up study of Indian villagers. *Community dentistry and oral epidemiology* 1980;8:283-333.
10. Pereira JS, Carvalho MV, Henriques AC, de Queiroz Camara TH, Miguel MC, Freitas RA. Epidemiology and correlation of the clinicopathologic features in oral epithelial dysplasia: analysis of 173 cases. *Ann Diagn Pathol* 2011;15:98-102.
11. van der Waal I. Potentially malignant disorders of the oral and oropharyngeal mucosa; present concepts of management. *Oral Oncol* 2010;46:423-5.
12. Mehta FS, Pindborg JJ, Gupta PC, Daftary DK. Epidemiologic and histologic study of oral cancer and leukoplakia among 50,915 villagers in India. *Cancer* 1969;24:832-49.
13. Axell T. Occurrence of leukoplakia and some other oral white lesions among 20333 adult Swedish people. *Community Dent Oral Epidemiol* 1987;15:51.
14. Shiu MN, Chen TH, Chang SH, Hahn LJ. Risk factors for leukoplakia and malignant transformation to oral carcinoma: a leukoplakia cohort of Taiwan. *Br J Cancer* 2000;82:1871-4.
15. Vora HH, Trivedi TI, Shukla SN, Shah NG, Goswami JV, Shah PM. p53 Expression in leukoplakia and carcinoma of the oral tongue. *Int J Biol Markers* 2006;21:74-80.
16. Lim K, Moles DR, Downer MC, Speight PM. Opportunistic screening for oral cancer and precancer in general dental practice: results of a demonstration study. *Br Dent J* 2003;194:497-502.
17. van der Waal I, Reichart PA. Oral proliferative verrucous leukoplakia revisited. *Oral Oncol* 2008;44:719-21.
18. Wei L, Wang YF, Zhou HW, Peng S, Zhou ZT, Tang GY. Malignant transformation of oral leukoplakia: a retrospective cohort study of 218 chinese patients. *BMC Cancer* 2010;10:685.

19. Gupta PC, Murti PR, Bhonsle RB. Epidemiology of cancer by tobacco products and the significance of TSNA. *Crit Rev Toxicol* 1996;26:183-98.
20. Maserejian NN, Joshipura KJ, Rosner BA, Giovannuci E, Zavras AI. Prospective study of alcohol consumption and risk of oral premalignant lesions in men. *Cancer Epidemiol Biomarkers Prev* 2006;15:774-81.
21. Saito T, Sugiura C, Hirai A, et al. Development of squamous cell carcinoma from pre-existent oral leukoplakia: with respect to treatment modality. *Int J Oral Maxillofac Surg* 2011;30:49-53.
22. Reichart PA. Identification of risk groups for oral precancer and cancer and preventive measures. *Clin Oral Invest* 2001;5:207-13.
23. Campisi G, Panzarella V, Giuliani M, et al. Human papillomavirus: its identity and controversial role in oral oncogenesis, premalignant and malignant lesions. *Int J Oncol* 2007;30:813-23.
24. Lee SY, Cho NH, Choi EC, et al. Relevance of human papilloma virus (HPV) infection to carcinogenesis of oral tongue cancer. *Int J Oral Maxillofac Surg* 2010;39:678-83.
25. Reibel J. Prognosis of oral premalignant lesions: significance of clinical, histopathological and molecular biological characteristics. *Crit Rev Oral Biol Med* 2003;14:47-62.
26. Pindborg JJ, Renstrup G, Poulsen HE, Silverman S, Jr. Studies in Oral Leukoplakias. V. Clinical and Histologic Signs of Malignancy. *Acta odontologica Scandinavica* 1963;21:407-14.
27. Warnakulasuriya S, Newell W, Johnson W, van der Waal I. Nomenclature and classification of potentially malignant disorders of the oral mucosa. *J Oral Pathol Med* 2007;36:575-80.
28. Warnakulasuriya S, Dietrich T, Bornstein MM, et al. Oral health risks of tobacco use and effects of cessation. *Int Dent J* 2010;60:7-30.
29. Gillenwater AM, Vigneswaran N, Fatani H, Saintigny P, El-Naggar AK. Proliferative verrucous leukoplakia (PVL): a review of an elusive pathologic entity! *Advances in anatomic pathology* 2013;20:416-23.
30. Haley JC, Hood AF, Mirowski GW. Proliferative verrucous leukoplakia with cutaneous involvement. *Journal of the American Academy of Dermatology* 1999;41:481-3.
31. van der Waal I, Reichart PA. Oral proliferative verrucous leukoplakia revisited. *Oral oncology* 2008;44:719-21.
32. Gandolfo S, Castellani R, Pentenero M. Proliferative verrucous leukoplakia: a potentially malignant disorder involving periodontal sites. *Journal of periodontology* 2009;80:274-81.
33. Bishen KA, Sethi A. Proliferative Verrucous Leukoplakia--diagnostic pitfalls and suggestions. *Medicina oral, patologia oral y cirugia bucal* 2009;14:E263-4.
34. Sieron A, Adamek M, Kawczyk-Krupka A, Mazur S, Ilewicz L. Photodynamic therapy (PDT) using topically applied delta-aminolevulinic acid (ALA) for the treatment of oral leukoplakia. *Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology* 2003;32:330-6.
35. Bouquot JE, Ephros H. Erythroplakia: the dangerous red mucosa. *Practical periodontics and aesthetic dentistry : PPAD* 1995;7:59-67; quiz 8.
36. Hashibe M, Mathew B, Kuruvilla B. Chewing tobacco, alcohol and the risk of erythroplakia. *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology* 2000;9:639-45.
37. Reichart PA, Philipsen HP. Oral erythroplakia--a review. *Oral oncology* 2005;41:551-61.
38. Villa A, Villa C, Abati S. Oral cancer and oral erythroplakia: an update and implications for clinicians. *Australian dental journal* 2011;56:253-6.
39. Ikeda N, Handa Y, Khim SP, et al. Prevalence study of oral mucosal lesions in a selected Cambodian population. *Community dentistry and oral epidemiology* 1995;23:49-54.

40. Ismail SB, Kumar SK, Zain RB. Oral lichen planus and lichenoid reactions: etiopathogenesis, diagnosis, management and malignant transformation. *Journal of oral science* 2007;49:89-106.
41. Rice PJ, Hamburger J. Oral lichenoid drug eruptions: their recognition and management. *Dental update* 2002;29:442-7.
42. Skoglund A, Egelrud T. Hypersensitivity reactions to dental materials in patients with lichenoid oral mucosal lesions and in patients with burning mouth syndrome. *Scandinavian journal of dental research* 1991;99:320-8.
43. Lartitegui-Sebastian MJ, Martinez-Revilla B, Saiz-Garcia C, Eguizabal-Saracho S, Aguirre-Urizar JM. Oral lichenoid lesions associated with amalgam restorations: a prospective pilot study addressing the adult population of the Basque Country. *Medicina oral, patologia oral y cirugia bucal* 2012;17:e545-9.
44. Larsson A, Warfvinge G. The histopathology of oral mucosal lesions associated with amalgam or porcelain-fused-to-metal restorations. *Oral diseases* 1995;1:152-8.
45. Sugerman PB, Savage NW. Oral lichen planus: causes, diagnosis and management. *Australian dental journal* 2002;47:290-7.
46. Garcia-Garcia V, Bascones-Martinez A, Garcia-Kass AI, et al. Analysis of the expression of heat-shock protein 27 in patients with oral lichen planus. *Oral diseases* 2013;19:65-72.
47. Chaiyarit P, Jintakanon D, Klanrit P, Siritapetawee M, Thongprasom K. Immunohistochemical analyses of survivin and heat shock protein 90 expression in patients with oral lichen planus. *Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology* 2009;38:55-62.
48. Andreasen JO. Oral lichen planus. 1. A clinical evaluation of 115 cases. *Oral surgery, oral medicine, and oral pathology* 1968;25:31-42.
49. Mignogna MD, Lo Russo L, Fedele S. Gingival involvement of oral lichen planus in a series of 700 patients. *Journal of clinical periodontology* 2005;32:1029-33.
50. Silverman S, Jr., Gorsky M, Lozada-Nur F. A prospective follow-up study of 570 patients with oral lichen planus: persistence, remission, and malignant association. *Oral surgery, oral medicine, and oral pathology* 1985;60:30-4.
51. Kreppel M, Hahner V, Backhaus T, et al. Orale Lichen planus (OLP und orale lichenoid Reaktion (OLR)). *Oralchirurgie Journal* 2013;3:8-14.
52. Eisenberg E. Oral lichen planus: a benign lesion. *Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons* 2000;58:1278-85.
53. Eisenberg E, Krutchkoff D. Diagnosis of oral lichen planus. *Journal of the American Dental Association* 1987;114:144, 6.
54. Scully C, Carrozzo M. Oral mucosal disease: Lichen planus. *The British journal of oral & maxillofacial surgery* 2008;46:15-21.
55. van der Meij EH, Reibel J, Slootweg PJ, van der Wal JE, de Jong WF, van der Waal I. Interobserver and intraobserver variability in the histologic assessment of oral lichen planus. *Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology* 1999;28:274-7.
56. Hadzi-Mihailovic M, Cakic S, Jankovic S, Raybaud H, Nedeljkovic N, Jankovic L. Ki-67 expression in oral lichen planus. *Journal of BUON : official journal of the Balkan Union of Oncology* 2012;17:132-7.
57. Lodi G, Scully C, Carrozzo M, Griffiths M, Sugerman PB, Thongprasom K. Current controversies in oral lichen planus: report of an international consensus meeting. Part 2. Clinical management and malignant transformation. *Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics* 2005;100:164-78.
58. Gonzalez-Moles MA, Scully C, Gil-Montoya JA. Oral lichen planus: controversies surrounding malignant transformation. *Oral diseases* 2008;14:229-43.
59. Lo Muzio L, Mignogna MD, Favia G, Procaccini M, Testa NF, Bucci E. The possible association between oral lichen planus and oral squamous cell carcinoma: a clinical evaluation on 14 cases and a review of the literature. *Oral oncology* 1998;34:239-46.

60. Rajenthiran R, McLean NR, Kelly CG, Reed MF, Nolan A. Malignant transformation of oral lichen planus. *European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology* 1999;25:520-3.
61. Gandolfo S, Richiardi L, Carrozzo M, et al. Risk of oral squamous cell carcinoma in 402 patients with oral lichen planus: a follow-up study in an Italian population. *Oral oncology* 2004;40:77-83.
62. Sharma A, Bialynicki-Birula R, Schwartz RA, Janniger CK. Lichen planus: an update and review. *Cutis; cutaneous medicine for the practitioner* 2012;90:17-23.
63. Carrozzo M, Gandolfo S. The management of oral lichen planus. *Oral diseases* 1999;5:196-205.
64. Holmstrup P, Schiotz AW, Westergaard J. Effect of dental plaque control on gingival lichen planus. *Oral surgery, oral medicine, and oral pathology* 1990;69:585-90.
65. Mansourian A, Momen-Heravi F, Saheb-Jamee M, Esfehiani M, Khalilzadeh O, Momen-Beitollahi J. Comparison of aloe vera mouthwash with triamcinolone acetonide 0.1% on oral lichen planus: a randomized double-blinded clinical trial. *The American journal of the medical sciences* 2011;342:447-51.
66. Thongprasom K, Luengvisut P, Wongwatanakij A, Boonjatturus C. Clinical evaluation in treatment of oral lichen planus with topical fluocinolone acetonide: a 2-year follow-up. *Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology* 2003;32:315-22.
67. Carbone M, Arduino PG, Carrozzo M, et al. Topical clobetasol in the treatment of atrophic-erosive oral lichen planus: a randomized controlled trial to compare two preparations with different concentrations. *Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology* 2009;38:227-33.
68. Isaac U, Issac JS, Ahmed Khoso N. Histopathologic features of oral submucous fibrosis: a study of 35 biopsy specimens. *Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics* 2008;106:556-60.
69. Bhonsle RB, Murti PR, Daftary DK, et al. Regional variations in oral submucous fibrosis in India. *Community dentistry and oral epidemiology* 1987;15:225-9.
70. Awan KH, Morgan PR, Warnakulasuriya S. Evaluation of an autofluorescence based imaging system (VELscope) in the detection of oral potentially malignant disorders and benign keratoses. *Oral oncology* 2011;47:274-7.
71. Gupta PC, Hebert JR, Bhonsle RB, Sinor PN, Mehta H, Mehta FS. Dietary factors in oral leukoplakia and submucous fibrosis in a population-based case control study in Gujarat, India. *Oral diseases* 1998;4:200-6.
72. Jacob BJ, Straif K, Thomas G, et al. Betel quid without tobacco as a risk factor for oral precancers. *Oral oncology* 2004;40:697-704.
73. Norton SA. Betel: consumption and consequences. *Journal of the American Academy of Dermatology* 1998;38:81-8.
74. Al-Attas SA, Ibrahim SS, Amer HA, Darwish Zel S, Hassan MH. Prevalence of potentially malignant oral mucosal lesions among tobacco users in Jeddah, Saudi Arabia. *Asian Pacific journal of cancer prevention : APJCP* 2014;15:757-62.
75. Bissessur S, Naidoo S. Areca nut and tobacco chewing habits in Durban, KwaZulu Natal. *SADJ : journal of the South African Dental Association = tydskrif van die Suid-Afrikaanse Tandheelkundige Vereniging* 2009;64:460-3.
76. Dayal, Reddy R, Anuradha Bhat K. Malignant potential of oral submucous fibrosis due to intraoral trauma. *Indian journal of medical sciences* 2000;54:182-7.
77. Ho MW. Patients with both oral leukoplakia and oral submucous fibrosis had a higher rate of malignant transformation compared to patients with oral leukoplakia or oral submucous fibrosis alone. *The journal of evidence-based dental practice* 2013;13:183-4.
78. Mehta FS, Daftary DK, Sahiar BE. A correlative histocytological study of epithelial atypia in leukoplakic and submucous fibrosis lesions amongst Indian villagers in a mass screening programme. *Indian journal of cancer* 1970;7:18-23.

79. Kreppel M, Drebber U, Eich HT, et al. Combined-modality treatment in advanced oral squamous cell carcinoma with primary surgery followed by adjuvant radiochemotherapy. *Strahlenther Onkol* 2011;187:555-60.
80. Kreppel M, Eich HT, Kübler AC, Zöller JE, Scheer M. Prognostic Value of the 6th Edition of the UICC's TNM Classification and Stage Grouping for Oral Cancer. *J Surg Oncol* 2010;102:443-9.
81. Kowalski LP, Franco EL, Torloni H, et al. Lateness of diagnosis of oral and oropharyngeal carcinoma: factors related to the tumour, the patient and health professionals. *Eur J Cancer B Oral Oncol* 1994;30B:167-73.
82. Messadi D, Wilder-Smith P, Wolinsky P. Improving oral cancer survival: the role of dental providers. *Journal of the California Dental Association* 2009;37:789-98.
83. Scheer M, Neugebauer J, Derman A, Fuss J, Drebber U, Zoeller JE. Autofluorescence imaging of potentially malignant mucosa lesions. *Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics* 2011;111:568-77.
84. Remmerbach TW, Mathes SN, Weidenbach H, Hemprich A, Bocking A. [Noninvasive brush biopsy as an innovative tool for early detection of oral carcinomas]. *Mund-, Kiefer- und Gesichtschirurgie : MKG* 2004;8:229-36.
85. Vashisht N, Ravikiran A, Samatha Y, Rao PC, Naik R, Vashisht D. Chemiluminescence and Toluidine Blue as Diagnostic Tools for Detecting Early Stages of Oral Cancer: An invivo Study. *Journal of clinical and diagnostic research : JCDR* 2014;8:ZC35-8.
86. Lam S, MacAulay C, Palcic B. Detection and localization of early lung cancer by imaging techniques. *Chest* 1993;103:12S-4S.
87. Park S, Follen M, Milbourne A. Automated image analysis of digital colposcopy for the detection of cervical neoplasia. *Journal of biomedical optics* 2008;13:014029.
88. Scheer M, Neugebauer J, Derman A, Fuss J, Drebber U, Zöller JE. Autofluorescence imaging of potentially malignant mucosa lesions. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2011;111:568-77.
89. Amorin C, Caffarena MP. [White lesions of the oral mucosa. Auxiliary diagnostic methods]. *Anales de la Facultad de Odontologia* 1990:21-6.
90. Reddy CR, Ramulu C, Sundareshwar B, Raju MV, Gopal R, Sarma R. Toluidine blue staining of oral cancer and precancerous lesions. *The Indian journal of medical research* 1973;61:1161-4.
91. Souyris F, Garzon E, Brami GS, Lamarche JP. [Simple test for the detection of precancerous lesions of the oral mucosa]. *Revue d'odonto-stomatologie du midi de la France* 1972;30:114-9.
92. Barrellier P, Babin E, Louis MY, Meunier-Guttin A. [The use of toluidine blue in the diagnosis of neoplastic lesions of the oral cavity]. *Revue de stomatologie et de chirurgie maxillo-faciale* 1993;94:51-4.
93. Richards D. Does toluidine blue detect more oral cancer? *Evidence-based dentistry* 2010;11:104-5.
94. Su WW, Yen AM, Chiu SY, Chen TH. A community-based RCT for oral cancer screening with toluidine blue. *Journal of dental research* 2010;89:933-7.
95. Patton L, Epstein J, Kerr A. Adjunctive techniques for oral cancer examination and lesion diagnosis: a systematic review of the literature. *Journal of the American Dental Association* 2008;139:896-905.
96. Remmerbach TW, Mathes SN, Weidenbach H, Hemprich A, Bocking A. [Noninvasive brush biopsy as an innovative tool for early detection of oral carcinomas]. *Mund Kiefer Gesichtschir* 2004;8:229-36.
97. Svirsky JA, Burns JC, Page DG, Abbey LM. Computer-assisted analysis of the oral brush biopsy. *Compendium of continuing education in dentistry* 2001;22:99-102, 4, 6; quiz 8.
98. Epstein JB, Gorsky M, Lonky S, Silverman S, Jr., Epstein JD, Bride M. The efficacy of oral lumenoscopy (ViziLite) in visualizing oral mucosal lesions. *Special care in dentistry : official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry* 2006;26:171-4.

99. Awan KH, Morgan PR, Warnakulasuriya S. Utility of chemiluminescence (ViziLite) in the detection of oral potentially malignant disorders and benign keratoses. *Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology* 2011;40:541-4.
100. Messadi DV. Diagnostic aids for detection of oral precancerous conditions. *International journal of oral science* 2013;5:59-65.
101. Li Y, John M, Zhou X. Salivary transcriptome diagnostics for oral cancer detection. *Clinical cancer research : an official journal of the American Association for Cancer Research* 2004;10:8442-50.
102. Metgud R, Patel S. Serum and salivary levels of albumin as diagnostic tools for oral pre-malignancy and oral malignancy. *Biotechnic & histochemistry : official publication of the Biological Stain Commission* 2014;89:8-13.
103. Mizukawa N, Sugiyama K, Ueno T, Mishima K, Takagi S, Sugahara T. Defensin-1, an antimicrobial peptide present in the saliva of patients with oral diseases. *Oral diseases* 1999;5:139-42.
104. Punyani SR, Sathawane RS. Salivary level of interleukin-8 in oral precancer and oral squamous cell carcinoma. *Clinical oral investigations* 2013;17:517-24.
105. van der Waal I, AxÇll T. Oral Leukoplakia: A Proposal for uniform reporting. *Oral Oncol* 2002;38:521-6.
106. Kreppel M, Kreppel B, Drebber U, et al. Podoplanin expression in oral leukoplakia: prognostic value and and clinicopathologic implications. *Oral Dis* 2012;doi: 10.1111/j.1601-0825.2012.01927.x.
107. Kujan O, Khattab A, Oliver RJ, Roberts SA, Thakker N, Sloan P. Why oral histopathology suffers inter-observer variability on grading oral epithelial dysplasia: An attempt to understand the sources of variation. *Oral Oncol* 2007;43:224-31.
108. Neid M, Tannapfel A. Intraepitheliale Plattenepithelneoplasie (WHO 2005). *HNO* 2009;57:181-8.
109. Gale N, Pilch BZ, Sidransky D, Westra WH, Califano J. Epithelial precursor lesions. *World Health Classification of tumours, Pathology and genetics of head and neck tumours: IARC Press, Lyon; 2005:140-3.*
110. Kujan O, Oliver RJ, Khattab A, Roberts SA, Thakker N, Sloan P. Evaluation of a new binary system of grading oral epithelial dysplasia for prediction of malignant transformation. *Oral Oncol* 2006;42:987-93.
111. Hellquist H, Cardesa A, Gale N, Kambic V, Michaels L. Criteria for grading in the Ljubljana classification of epithelial hyperplastic laryngeal lesions. A study by members of the Working Grouping on Epithelial Hyperplastic Laryngeal Lesions of the European Society of Pathology. *Histopathology* 1999;34:226-33.
112. Kambic V, Lenart I. Notre classification des hyperplasies de l'ÇpithÇlium du larynx au point de vue pronostic. *J Fr Otorhinolaryngol Audiophonol Chir Maxillofac* 1971;20:1145-50.
113. Gale N, Zidar N, Fischinger J, Kambic V. Clinical applicability of the Ljubljana classification of epithelial hyperplastic laryngeal lesions. *Clin Otolaryngol* 2000;25:227-32.
114. Mahajan M, Hazarey VK. An assessment of oral epithelial dysplasia using criteria of Smith and Pindborg's grading system and Ljubljana grading system in oral precancer lesions. *J Oral Maxillofac Pathol* 2004;8:73-81.
115. Amagasa T, Yamashiro M, Ishikawa H. Oral leukoplakia related to malignant transformation. *Oral Sci Int* 2006;3:45-55.
116. Cowan CG, Gregg TA, Napier SS, McKenna SM, Kee F. Potentially malignant oral lesions in Northern Ireland: A 20-year population-based perspective of malignant transformation. *Oral Dis* 2001;7:18-24.
117. Schepman KP, van der Meij EH, Smeele LE, van der Waal I. Malignant transformation of oral leukoplakia: a follow-up study of a hospital-based population of 166 patients with oral leukoplakia from The Netherlands. *Oral oncology* 1998;34:270-5.
118. Speight PM, Farthing PM, Bouquot JE. The pathology of oral cancer and precancer. *Current Diagnostic Pathology* 1996;3:165-76.
119. Holmstrup P, Vedtofte P, Reibel J, Stoltze K. Long-term treatment outcome of oral premalignant lesions. *Oral oncology* 2006;42:461-74.

120. Schepman KP, van der Waal I. A proposal for a classification and staging system for oral leukoplakia: a preliminary study. *Eur J Cancer B Oral Oncol* 1995;32B:396-8.
121. Silverman S, Jr., Gorsky M, Lozada F. Oral leukoplakia and malignant transformation: a follow-up study of 257 patients. *Cancer* 1984;53:563-8.
122. Kreppel M, Eich HT, Brüggenolte C, et al. Preoperative vs. postoperative radiochemotherapy in patients with N2 squamous cell carcinoma of the oral cavity. *Oral Oncol* 2012;Epub ahead of print:DOI: 10.1016/j.oraloncology.2012.04.001.
123. Gupta PC. Leukoplakia and incidence of oral cancer. *Journal of oral pathology & medicine* : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 1989;18:17.
124. Tabor MP, Braakhuis BJM, van der Waal JE, et al. Comparative molecular and histological grading of epithelial dysplasia of the oral cavity and the oropharynx. *J Pathol* 2003;199:354-60.
125. Lind PO. Malignant transformation in oral leukoplakia. *Scand J Dent Res* 1987;95:449-55.
126. Warnakulasuriya S, Reibel J, Bouquot J, Dabelsteen E. Oral epithelial dysplasia classification systems: predictive value, utility, weakness and scope for improvement. *J Oral Pathol Med* 2008;37:127-33.
127. Bánóczy J. Follow-up studies in oral leukoplakia. *J Maxillofac Surg* 1977;5:69-75.
128. Pindborg JJ, Jolst O, Renstrup G, Roed-Petersen B. Studies in oral leukoplakia: a preliminary report on the period prevalence of malignant transformation in leukoplakia based on a follow-up study of 248 patients. *J Am Dent Assoc* 1968;76:767-71.
129. van der Waal I, Schepman KP, van der Meij EH. A modified classification and staging system for oral leukoplakia. *Oral Oncol* 2000;36:264-6.
130. Lippman SM, Heymach JV. The convergent development of molecular-targeted drugs for cancer treatment and prevention. *Clin Cancer Res* 2007;13:4035-41.
131. Lele S. Although leukoplakia responds to some treatments relapses and adverse effects are common. *Evid Based Dent* 2005;6:15-6.
132. Lodi G, Sardella A, Bez C, Demarosi F, Carrassi F. Systematic review of randomized trials for the treatment of oral leukoplakia. *J Dent Educ* 2002;66:896-902.
133. Scheifele C, Reichart PA. Orale Leukoplakien beim manifesten Plattenepithelkarzinom. *Mund Kiefer GesichtsChir* 1998;2:326-30.
134. Ang KK, Harris J, Wheeler R, et al. Human Papillomavirus and Survival in Patients with Oropharyngeal Cancer. *N Engl J Med* 2010;363:24-35.
135. Gillison ML. Current topics in the epidemiology of oral cavity and oropharyngeal cancer. *Head Neck* 2007;29:779-92.
136. Nakahara y, shintani S, Mihara M. Alterations of Rb, p16(INK4A) and cyclin D1 in the tumorigenesis of oral squamous cell carcinomas. *Cancer letters* 2000;160:3-8.
137. Miller CS, Johnstone BM. Human papillomavirus as a risk factor for oral squamous cell carcinoma: a meta-analysis, 1982-1997. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2001;91:622-35.